2026-06-14T03:42:03Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/116012025-05-05T09:11:39Zcom_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_19617

00925njm 22002777a 4500 dc Garranzo-Asensio, Maria author Segundo-Acosta, Pablo San author Poves, Carmen author Fernández-Aceñero, María Jesús author Martínez-Useros, Javier author Montero-Calle, Ana Maria author Solis-Fernandez, Guillermo author Sanchez-Martinez, Maricruz author Rodríguez, Nuria author Cerón, María-Ángeles author Fernandez-Diez, Servando author Domínguez, Gemma author de los Ríos, Vivian author Peláez-García, Alberto author Guzmán-Aránguez, Ana author Barderas Manchado, Rodrigo author 2020 Colorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer related death worldwide. Its diagnosis at early stages would significantly improve the survival of CRC patients. The humoral immune response has been demonstrated useful for cancer diagnosis, predating clinical symptoms up to 3 years. Here, we employed an in-depth seroproteomic approach to identify proteins that elicit a humoral immune response in CRC patients. The seroproteomic approach relied on the immunoprecipitation with patient-derived autoantibodies of proteins from CRC cell lines with different metastatic properties followed by LC-MS/MS. After bioinformatics, we focused on 31 targets of CRC autoantibodies. After WB and IHC validation, ERP44 and TALDO1 showed potential to discriminate disease-free and metastatic CRC patients, and time to recurrence of CRC patients in stage II. Using plasma samples of 30 healthy individuals, 28 premalignant individuals, and 32 CRC patients, nine out of 13 selected targets for seroreactive analysis showed significant diagnostic ability to discriminate either CRC patients or premalignant subjects from controls. Our results suggest that the here defined panel of CRC autoantibodies and their target proteins should be included in CRC blood-based biomarker panels to get a clinically useful blood-based diagnostic signature for CRC detection. SIGNIFICANCE: Colorectal cancer is one of the deadliest cancer types mainly due to its late diagnosis. Its early diagnosis, therefore, is of great importance since it would significantly improve the survival of CRC patients. In our work, the in-depth seroproteomic analysis of colorectal cancer using isolated IgGs from colorectal cancer patients and controls and protein extract of colorectal cancer cells provide the identification of valuable biomarkers with diagnostic and prognostic ability of the disease. J Proteomics. 2020 Mar 1;214:103635. 10.1016/j.jprot.2020.103635 1876-7737 Journal of proteomics 31918032 http://hdl.handle.net/20.500.12105/11601 Colorectal cancer Immune response Seroproteomics Diagnostic autoantibody biomarkers Mass spectrometry Identification of tumor-associated antigens with diagnostic ability of colorectal cancer by in-depth immunomic and seroproteomic analysis